Rubeen Israni

626 total citations · 1 hit paper
16 papers, 413 citations indexed

About

Rubeen Israni is a scholar working on Nephrology, Pulmonary and Respiratory Medicine and Hematology. According to data from OpenAlex, Rubeen Israni has authored 16 papers receiving a total of 413 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Nephrology, 5 papers in Pulmonary and Respiratory Medicine and 3 papers in Hematology. Recurrent topics in Rubeen Israni's work include Dialysis and Renal Disease Management (5 papers), Potassium and Related Disorders (4 papers) and Erythropoietin and Anemia Treatment (3 papers). Rubeen Israni is often cited by papers focused on Dialysis and Renal Disease Management (5 papers), Potassium and Related Disorders (4 papers) and Erythropoietin and Anemia Treatment (3 papers). Rubeen Israni collaborates with scholars based in United States, United Kingdom and India. Rubeen Israni's co-authors include Harold I. Feldman, Marshall M. Joffe, Wei Yang, Steven M. Brunelli, Steven Fishbane, Jeffrey S. Berns, Judy A. Shea, Nishaminy Kasbekar, Kevin Haynes and Steven Fishbane and has published in prestigious journals such as Kidney International, Journal of the American Society of Nephrology and American Journal of Kidney Diseases.

In The Last Decade

Rubeen Israni

15 papers receiving 397 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathy

2024 51 citations Richard Lafayette, Sean Barbour et al. Kidney International profile →

Peers

Rubeen Israni

NEPHR

HEMAT

GENET

PRM

PPCH

Claire H. den Hoedt Netherlands

Maria Larkina United States

Marvin Sinsakul United States

César García-Cantón Spain

Heleen van Haalen Sweden

Kai Uwe Eckardt Germany

Brian Wasserman United States

Cindy Huang United States

C Deighan United Kingdom

Antonio Lopes Brazil

Claire H. den Hoedt Netherlands

Rubeen Israni

596 ×2.5

NEPHR

190 ×0.9

HEMAT

95 ×1.1

GENET

36 ×0.8

PRM

30 ×0.8

PPCH

Citations per year, relative to Rubeen Israni Rubeen Israni (= 1×) peers Claire H. den Hoedt

Countries citing papers authored by Rubeen Israni

Since Specialization

Citations

This map shows the geographic impact of Rubeen Israni's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rubeen Israni with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rubeen Israni more than expected).

Fields of papers citing papers by Rubeen Israni

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rubeen Israni. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rubeen Israni. The network helps show where Rubeen Israni may publish in the future.

Co-authorship network of co-authors of Rubeen Israni

This figure shows the co-authorship network connecting the top 25 collaborators of Rubeen Israni. A scholar is included among the top collaborators of Rubeen Israni based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rubeen Israni. Rubeen Israni is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

Lafayette, Richard, Sean Barbour, Rubeen Israni, et al.. (2024). A phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathy. Kidney International. 105(6). 1306–1315. 51 indexed citations breakdown →

Barratt, Jonathan, Bart Maes, Rubeen Israni, et al.. (2024). WCN24-1414 ORIGIN 3: PIVOTAL PHASE 3 STUDY EVALUATING EFFECT OF ATACICEPT VS PLACEBO ON PROTEINURIA AND RENAL FUNCTION PRESERVATION IN IGA NEPHROPATHY. Kidney International Reports. 9(4). S164–S164.

Lafayette, Richard, Bart Maes, Rubeen Israni, et al.. (2024). #812 Phase 2b ORIGIN study open label extension with atacicept in patients with IgA nephropathy and persistent proteinuria: week 72 interim analysis. Nephrology Dialysis Transplantation. 39(Supplement_1). 3 indexed citations

Johansen, Kirsten L., Alexander R. Cobitz, Ajay Singh, et al.. (2023). The ASCEND-NHQ randomized trial found positive effects of daprodustat on hemoglobin and quality of life in patients with non-dialysis chronic kidney disease. Kidney International. 103(6). 1180–1192. 16 indexed citations

Johansen, Kirsten L., Fredric O. Finkelstein, Csaba P. Kövesdy, et al.. (2022). Effects of Daprodustat on Hemoglobin and Quality of Life in Non-Dialysis CKD Patients: Expanded Results of the ASCEND-NHQ Trial. Journal of the American Society of Nephrology. 33(11S). 244–244. 2 indexed citations

Cook, Erin, Jill Davis, Rubeen Israni, et al.. (2021). Prevalence of Metabolic Acidosis Among Patients with Chronic Kidney Disease and Hyperkalemia. Advances in Therapy. 38(10). 5238–5252. 5 indexed citations

Israni, Rubeen, Keith A. Betts, Fan Mu, et al.. (2021). Determinants of Hyperkalemia Progression Among Patients with Mild Hyperkalemia. Advances in Therapy. 38(11). 5596–5608. 4 indexed citations

Davis, Jill, Rubeen Israni, Fan Mu, et al.. (2021). Inpatient management and post-discharge outcomes of hyperkalemia. Hospital Practice. 49(4). 273–279. 4 indexed citations

Davis, Jill, Rubeen Israni, Keith A. Betts, et al.. (2021). Real-World Management of Hyperkalemia in the Emergency Department: An Electronic Medical Record Analysis. Advances in Therapy. 39(2). 1033–1044. 5 indexed citations

10.

Olufade, Temitope, Like Jiang, Rubeen Israni, Joanna Huang, & Aidar R. Gosmanov. (2021). Cardiovascular and renal disease manifestation and healthcare resource utilization in patients on first‐line oral therapy for type 2 diabetes: A claims‐based observational cohort study. Diabetes Obesity and Metabolism. 23(12). 2741–2751. 7 indexed citations

11.

Cobitz, Alexander R., Renato D. Lópes, Ajay Singh, et al.. (2021). Effects of Daprodustat on Hemoglobin and Quality of Life in Patients with CKD: Results of the ASCEND-NHQ Randomized, Double-Blind, Placebo-Controlled Trial. Journal of the American Society of Nephrology. 32(10S). 36–36. 3 indexed citations

12.

Israni, Rubeen, Judy A. Shea, Marshall M. Joffe, & Harold I. Feldman. (2009). Physician Characteristics and Knowledge of CKD Management. American Journal of Kidney Diseases. 54(2). 238–247. 39 indexed citations

13.

Brunelli, Steven M., Marshall M. Joffe, Rubeen Israni, et al.. (2008). History-Adjusted Marginal Structural Analysis of the Association between Hemoglobin Variability and Mortality among Chronic Hemodialysis Patients. Clinical Journal of the American Society of Nephrology. 3(3). 777–782. 63 indexed citations

14.

Yang, Wei, Rubeen Israni, Steven M. Brunelli, et al.. (2007). Hemoglobin Variability and Mortality in ESRD. Journal of the American Society of Nephrology. 18(12). 3164–3170. 153 indexed citations

15.

Israni, Rubeen, Nishaminy Kasbekar, Kevin Haynes, & Jeffrey S. Berns. (2006). Use of Antiepileptic Drugs in Patients with Kidney Disease. Seminars in Dialysis. 19(5). 408–416. 35 indexed citations

16.

Israni, Ajay K., Scott D. Halpern, Christopher B. McFadden, et al.. (2004). Willingness of dialysis patients to participate in a randomized controlled trial of daily dialysis. Kidney International. 65(3). 990–998. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact